| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Texas Children's Cancer Center, Baylor College of Medicine, Houston, Texas, USA
Correspondence: Lisa Bomgaars, M.D., 6621 Fannin Street, MC 3-3320, Houston, Texas 77030-2399, USA. Telephone: 832-824-4588; Fax: 832-825-4039; e-mail: lbomgaars{at}txccc.org
Camptothecin analogs, agents that target the intranuclear enzyme topoisomerase I, represent a promising new class of anticancer drugs for the treatment of childhood cancer. In preclinical studies, camptothecins, such as topotecan and irinotecan, are highly active against a variety of pediatric malignancies including neuroblastomas, rhabdomyosarcomas, gliomas, and medulloblastomas. In this paper, we review the status of completed and ongoing clinical trials and pharmacokinetic studies of camptothecin analogs in children. These and future planned studies of this novel class of cytotoxic agents are critical to defining the ultimate role of topoisomerase I poisons in the treatment of childhood cancer.
This article has been cited by other articles:
 |
|
 |
|
  M. Puppo, F. Battaglia, C. Ottaviano, S. Delfino, D. Ribatti, L. Varesio, and M. C. Bosco Topotecan inhibits vascular endothelial growth factor production and angiogenic activity induced by hypoxia in human neuroblastoma by targeting hypoxia-inducible factor-1{alpha} and -2{alpha} Mol. Cancer Ther., July 1, 2008; 7(7): 1974 - 1984. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Panetta, P. Schaiquevich, V. M. Santana, and C. F. Stewart Using Pharmacokinetic and Pharmacodynamic Modeling and Simulation to Evaluate Importance of Schedule in Topotecan Therapy for Pediatric Neuroblastoma Clin. Cancer Res., January 1, 2008; 14(1): 318 - 325. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Metzger, C. F. Stewart, B. B. Freeman III, C. A. Billups, F. A. Hoffer, J. Wu, M. J. Coppes, R. Grant, M. Chintagumpala, E. A. Mullen, et al. Topotecan Is Active Against Wilms' Tumor: Results of a Multi-Institutional Phase II Study J. Clin. Oncol., July 20, 2007; 25(21): 3130 - 3136. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. F. Stewart, J. C. Panetta, M. A. O'Shaughnessy, S. L. Throm, C. H. Fraga, T. Owens, T. Liu, C. Billups, C. Rodriguez-Galindo, A. Gajjar, et al. UGT1A1 Promoter Genotype Correlates With SN-38 Pharmacokinetics, but Not Severe Toxicity in Patients Receiving Low-Dose Irinotecan J. Clin. Oncol., June 20, 2007; 25(18): 2594 - 2600. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Vassal, D. Couanet, E. Stockdale, A. Geoffray, B. Geoerger, D. Orbach, F. Pichon, J. C. Gentet, S. Picton, C. Bergeron, et al. Phase II Trial of Irinotecan in Children With Relapsed or Refractory Rhabdomyosarcoma: A Joint Study of the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group J. Clin. Oncol., February 1, 2007; 25(4): 356 - 361. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Mora, O. Cruz, S. Gala, and R. Navarro Successful treatment of childhood intramedullary spinal cord astrocytomas with irinotecan and cisplatin Neuro-oncol, January 1, 2007; 9(1): 39 - 46. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-G. Song, S.-M. Gao, K.-M. Du, M. Xu, Y. Yu, Y.-H. Zhou, Q. Wang, Z. Chen, Y.-S. Zhu, and G.-Q. Chen Nanomolar concentration of NSC606985, a camptothecin analog, induces leukemic-cell apoptosis through protein kinase C{delta}-dependent mechanisms Blood, May 1, 2005; 105(9): 3714 - 3721. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Smith and B. D. Anderson A Window on Reality? J. Clin. Oncol., April 15, 2004; 22(8): 1360 - 1362. [Full Text] [PDF]
|
|
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| THE ONCOLOGIST | STEM CELLS | CME | ALPHAMED PRESS JOURNALS |
